PLYX
Polaryx Therapeutics, Inc. Common Stock
There isn't enough reported data to score PLYX yet.
PLYX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
PLYX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
PLYX PE Valuation
PLYX has no meaningful PE right now: it lost money over the past year.
PLYX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Moderate |
Analysts expect PLYX's losses to grow, with revenue holding steady.
PLYX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.18 | -$0.14 |
| Q2 2026 | -$0.12 | -$0.08 |
PLYX lost $0.18 per share over the past year, and its loss has widened in each of the last four quarters.
PLYX Quarterly Revenue
PLYX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.1M | -$2.2M |
| Q2 2026 | -$1.4M | -$511K |
| Q1 2026 | -$2.1M | -$1.4M |
| Q4 2025 | -$1.5M | -$630K |
| Q3 2025 | -$887K | +$445K |
PLYX has burned cash in almost every quarter: −$8M over the past year, against −$3M the year before.
PLYX Net Leverage
PLYX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
PLYX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 15.3 | Oversold |
| Stochastic | 10.1 | Oversold |
PLYX's weekly RSI is 15 (oversold) and its Stochastic is 10 (oversold).
PLYX PE vs Healthcare Sector
PLYX has no meaningful PE right now: it lost money over the past year.
PLYX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.92 | 2.1% below |
| 20 week MA | $2.11 | 11% below |
PLYX is in a downtrend: it's below all two of its weekly moving averages, and 11% below its 20-week average.
PLYX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $8.91 | $1.88 | -79% |
It's down 79% so far in 2026.